Moxifloxacinum Misom, (Moxifloxacin Hydrochloride)

Moxifloxacinum Misom is a fluoroquinolone ophthalmic antibacterial used to manage bacterial eye infections.

• Bacterial conjunctivitis: reduces bacterial load and resolves redness and discharge.
• Bacterial keratitis: eradicates pathogenic bacteria to prevent corneal damage.
• Post‑operative ocular infection: prevents or treats infection following eye surgery.

• Moxifloxacin Hydrochloride inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. By blocking these targets, the drug prevents bacterial cell division and leads to bacterial death, providing a bactericidal effect against susceptible ocular pathogens.

Moxifloxacinum Misom may cause ocular and systemic reactions.

Common Side Effects

• Eye irritation: mild burning or stinging on instillation.
• Redness: transient conjunctival hyperemia.
• Blurred vision: temporary visual disturbance after dosing.
• Tearing: increased lacrimation.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Allergic reaction: swelling, rash, or hives requiring medical attention.
• Stevens‑Johnson syndrome: severe skin and mucous membrane involvement.
• Corneal ulceration: worsening corneal lesions despite therapy.
• Anaphylaxis: rapid onset of systemic hypersensitivity.
• Severe ocular inflammation: marked pain, photophobia, and vision loss.

Before prescribing Moxifloxacinum Misom, consider the following safety measures.

• Allergy assessment: avoid if known hypersensitivity to fluoroquinolones.
• Contact lens use: discontinue lenses during treatment to reduce irritation.
• Corneal ulcer monitoring: assess response and adjust therapy if condition worsens.
• Pregnancy safety: use only if potential benefit justifies potential risk.
• Pediatric use: safety and efficacy not established in children.
• Store at room temperature: keep in original container, protect from light and moisture.

Moxifloxacinum Misom can interact with other ophthalmic and systemic agents.

Major Interactions (Avoid)

• Systemic fluoroquinolones: concurrent use may increase systemic exposure.
• Corticosteroid eye drops: may heighten risk of secondary infection.
• Anticholinergic eye drops: can reduce drug absorption.
• Tetracycline antibiotics: potential for additive phototoxicity.
• Non‑steroidal anti‑inflammatory eye drops: may impair healing.

Moderate Interactions (Monitor Closely)

• Other topical antibiotics: assess for additive toxicity.
• Ocular anesthetics: monitor for delayed corneal healing.
• Herbal supplements (e.g., St. John’s wort): may affect metabolism.
• Vitamin A derivatives: watch for altered ocular surface response.